---
title: "Polypill Improved Ejection Fraction in HFrEF Trial"
id: "nature-4-polypill-for-heart-failure-with-reduced-ejection-fraction-the-poly-hf"
canonical_url: "https://medichelpline.com/clinical-feed/nature-4-polypill-for-heart-failure-with-reduced-ejection-fraction-the-poly-hf"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04504-5"
published_at: "2026-07-02T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Polypill Improved Ejection Fraction in HFrEF Trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-4-polypill-for-heart-failure-with-reduced-ejection-fraction-the-poly-hf
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04504-5)
- **Published At:** 2026-07-02T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Heart failure with reduced ejection fraction carries a poor prognosis. Although guideline-directed medical therapy reduces morbidity and mortality, its real-world utilization is low. Accordingly, we conducted an open-label randomized trial (POLY-HF) at two centers enrolling a predominantly underserved population to test whether a polypill strategy improves cardiac function in heart failure. Adults with heart failure and left ventricular ejection fraction ≤40% were randomized to a once-daily polypill containing metoprolol succinate (25/50/100/150 mg), spironolactone 12.5 mg and empagliflozin 10 mg, or rapid uptitration of individual guideline-directed medical therapy medications (‘enhanced usual care’). Participants also continued treatment with a renin-angiotensin system inhibitor or sacubitril/valsartan as a separate pill. The primary endpoint was ejection fraction as assessed by cardiac magnetic resonance imaging at 6 months. Secondary endpoints included clinical outcomes and adherence. We randomized 212 patients (median age 54 years, 22% female, 54% Black). Follow-up magnetic resonance imaging data were available for 187 (88%) participants who were included in the modified intention-to-treat analysis.
## Clinical Analysis & Structured Key Points
Nature Medicine published a clinical update in Research Highlights on 02 Jul 2026. The item focuses on Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Review the original article for the full source wording and details.
## Related Clinical Research

- [Biochemical profile of spironolactone use in hospitalized patients with hypotonic hyponatraemia](https://medichelpline.com/clinical-feed/pubmed-42752325.md) (DOI: 10.1080/07853890.2026.2718576)
- [Coexisting AL (λ) amyloidosis and POEMS syndrome presenting as refractory heart failure: a case re](https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-a-rare-coexistence-of-immunoglobulin-light-chain-amyloidosis-and-poems-syndrome.md)
- [Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-12-finerenone-prescriptions-in-the-united-states-2021-2024-by-physician-specialty.md)
- [Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials](https://medichelpline.com/clinical-feed/medrxiv-8-heterogeneous-treatment-effects-in-hfpef-distinguishing-drug-specific-response.md)
- [Spironolactone and early eGFR declines in HFpEF: TOPCAT Americas post-hoc analysis](https://medichelpline.com/clinical-feed/pubmed-41961632.md) (DOI: 10.1093/ejhf/xuag099)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.